Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines


2020 vision: A look at the future of the biosimilars market

Countdown to US biosimilars has begun, though drugmakers suggest 2017 could be the year for launch takes a look at the players, patent expiries and legal wrangles that will dominate the biosimilars market over the next few years. 

Related news

News in brief

Patheon has acquired Gallus BioPharmaceuticals adding two US biologics plants and says with an industry shift towards medium sized bioreactors it now holds the market advantage.

Merck Millipore has set out to win more biomanufacturing business in Japan by consolidating testing and technical operations in the country into a newly expanded Tokyo training hub.

A US FDA reinspection of Alexion’s Rhode Island facility hit with a warning letter last year has resulted in a Form 483 with three observations.

Johnson & Johnson subsidiary Janssen has acquired monoclonal antibody (mAb) platform FynomAb through its purchase of private Swiss biopharma company Covagen.

Global Industry News

Standardising trial measurements could stop ‘wasteful’ research from

Regulators are showing interest in a database of clinical trial endpoints to cut redundant research, although contract research organisation Parexel has expressed reservations.


Is Pfizer now eyeing up Actavis three months after failed AZ bid? from

Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant? In-Pharmatechnologist investigates.

GSK: GM yeast breakthrough won't kill off poppy-based opium from

Poppies will continue to be the main source of industrial opiates long-term according to GSK, despite a recent breakthrough in efforts to produce it in GM yeast.

If it’s an IATA certified cold chain, this must be Belgium from

Brussels airport has become the first European shipping hub to adopt a cold-chain certification programme for pharmaceutical cargo that industry group IATA claims “goes beyond” GDP requirements.

People on the Move

People on the Move from

Regulatory experts dominate this week's column on who's who in pharmaceutical outsourcing.

US claims Dr Reddy’s broke safety packaging rules for 4 years from

Dr Reddy’s Laboratories says accusations by the US Government’s Consumer Product Safety Commission (CPSC) that it violated childproof packaging rules could cause significant losses for the company.


Kentucky firm ramps production of plant-based antibodies for Ebola

Kentucky firm ramps production of plant-based antibodies used to treat two Ebola patients

Two Americans stricken with the Ebola virus in Liberia were flown back to the US following treatment...

Pfizer buys Baxter's vaccine business plus Austrian plant for $635m

Pfizer buys Baxter's vaccine business plus Austrian plant for $635m

Pfizer has agreed to pay $635m (€474m) to Baxter International for its vaccine business, including two marketed...

Where are tomorrow’s biosimilar hotspots?

Where are tomorrow’s biosimilar hotspots?

As the US FDA (Food and Drug Administration)’s biosimilars pathway is tested for the first known time...

GSK files world’s first malaria vaccine

GSK files world’s first malaria vaccine

GSK has submitted an application for the world’s first malaria vaccine to the European Medicines Agency (EMA)....

J&J's Janssen remains confident in Remicade despite biosimilar threat

Biosimilars will not erode sales like generics, says J&J

Biosimilars are not analogous to small molecule generics in terms of market share loss according to Johnson...